Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a quadruple therapy regimen used for the eradication of Helicobacter pylori infection, particularly as a rescue treatment after failure of standard triple therapy. The combination works through multiple mechanisms to eliminate H. pylori bacteria from the stomach and duodenum. Pantoprazole reduces stomach acid production, creating a less acidic environment. Bismuth disrupts bacterial cell membranes and increases the effects of antibiotics. Tetracycline inhibits bacterial protein synthesis. Tinidazole (similar to metronidazole) damages bacterial DNA. This combination therapy is typically administered for 7-10 days.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bismuth + pantoprazole + tetracycline + tinidazole.